Alpha 2.0
Login Register
» Articles » PMID: 23299380

2012: A Watershed Year for Alzheimer's Disease Research

Overview
Journal J Nutr Health Aging
Specialties Geriatrics
Nutritional Sciences
Date 2013 Jan 10
PMID 23299380
Citations 11
Authors
M Grundman
A Dibernardo
N Raghavan
M Krams
E Yuen
Affiliations
Soon will be listed here.
Abstract

Despite negative topline phase 3 clinical trial results for bapineuzumab and solanezumab in mild to moderate AD, findings from these trials and recent advances suggest renewed optimism for anti-amyloid therapies. Aβ immunotherapy has now demonstrated its ability to engage CNS Aβ and modify downstream CNS biomarkers in bapineuzumab treated patients, and to show likely cognitive benefits in mild patients treated with solanezumab. The current availability of potent BACE inhibitors provides additional opportunities to test the value of reducing Aβ in the clinic. Trial enhancements, such as selecting and enriching for early stage AD, treating participants longer and using more sensitive composite endpoints may further improve our chances of demonstrating clinical efficacy and securing beneficial treatments for patients.

Citing Articles

Use of Peptides for the Management of Alzheimer's Disease: Diagnosis and Inhibition.

Baig M, Ahmad K, Rabbani G, Choi I Front Aging Neurosci. 2018; 10:21.

PMID: 29467644 PMC: 5808296. DOI: 10.3389/fnagi.2018.00021.

Efficacy and safety of anti-amyloid- immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis.

Mo J, Li J, Yang Z, Liu Z, Feng J Ann Clin Transl Neurol. 2018; 4(12):931-942.

PMID: 29296624 PMC: 5740249. DOI: 10.1002/acn3.469.

An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice.

Cheng Y, Chen Z, Liao T, Lin C, Shen H, Wang Y EMBO Mol Med. 2017; 9(5):703-715.

PMID: 28356312 PMC: 5412883. DOI: 10.15252/emmm.201606666.

Can insulin signaling pathways be targeted to transport Aβ out of the brain?.

Vandal M, Bourassa P, Calon F Front Aging Neurosci. 2015; 7:114.

PMID: 26136681 PMC: 4468380. DOI: 10.3389/fnagi.2015.00114.

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.

Grill J, Raman R, Ernstrom K, Aisen P, Dowsett S, Chen Y Alzheimers Res Ther. 2015; 7(1):39.

PMID: 26120368 PMC: 4481112. DOI: 10.1186/s13195-015-0122-5.

References
1.
Samtani M, Raghavan N, Shi Y, Novak G, Farnum M, Lobanov V . Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol. 2012; 75(1):146-61. PMC: 3555054. DOI: 10.1111/j.1365-2125.2012.04308.x. View
2.
Raghavan N, Samtani M, Farnum M, Yang E, Novak G, Grundman M . The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement. 2012; 9(1 Suppl):S21-31. PMC: 3732822. DOI: 10.1016/j.jalz.2012.05.2187. View
3.
Jonsson T, Atwal J, Steinberg S, Snaedal J, Jonsson P, Bjornsson S . A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012; 488(7409):96-9. DOI: 10.1038/nature11283. View
4.
Bateman R, Xiong C, Benzinger T, Fagan A, Goate A, Fox N . Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367(9):795-804. PMC: 3474597. DOI: 10.1056/NEJMoa1202753. View
5.
Yang L, Rieves D, Ganley C . Brain amyloid imaging--FDA approval of florbetapir F18 injection. N Engl J Med. 2012; 367(10):885-7. DOI: 10.1056/NEJMp1208061. View